Your browser doesn't support javascript.
loading
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era.
Kim, Isaac E; Jang, Thomas L; Kim, Sinae; Lee, David Y; Kim, Daniel D; Singer, Eric A; Ghodoussipour, Saum; Stein, Mark N; Aron, Monish; Dall'Era, Marc A; Yi Kim, Isaac.
Affiliation
  • Kim IE; Warren Alpert Medical School, Brown University, Providence, RI, USA.
  • Jang TL; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey, New Brunswick, NJ, USA.
  • Kim S; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, The State University of New Jersey, Piscataway, NJ, USA.
  • Lee DY; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey, New Brunswick, NJ, USA.
  • Kim DD; Warren Alpert Medical School, Brown University, Providence, RI, USA.
  • Singer EA; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey, New Brunswick, NJ, USA.
  • Ghodoussipour S; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey, New Brunswick, NJ, USA.
  • Stein MN; Department of Internal Medicine, Division of Medical Oncology, Columbia University, New York, NY, USA.
  • Aron M; Department of Urology, University of Southern California, Los Angeles, CA, USA.
  • Dall'Era MA; Department of Urologic Surgery, University of California Davis, Sacramento, CA, USA.
  • Yi Kim I; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey, New Brunswick, NJ, USA.
Cancer Med ; 10(22): 7909-7920, 2021 11.
Article in En | MEDLINE | ID: mdl-34713977
ABSTRACT
Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to assess the survival outcome of metastatic prostate cancer patients since 2000. The results demonstrated that there was an improvement in both overall and prostate cancer-specific survival for 4 months among men diagnosed with metastatic prostate cancer from 2010 to 2016 when compared to those in the pre-2010 period. Interestingly, this survival benefit was limited to patients with bone and visceral metastasis (M1b and M1c stages). Collectively, our observation suggests that despite the new treatment agents such as second-line antiandrogen therapies introduced in the modern era, the improvement in survival of metastatic prostate cancer patients has been surprisingly small.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Androgen Antagonists Type of study: Diagnostic_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Cancer Med Year: 2021 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Androgen Antagonists Type of study: Diagnostic_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Cancer Med Year: 2021 Document type: Article Affiliation country: United States